OS Therapies Inc. OSTX 深 滬
等待開盤 10-31 09:30:00 美东时间
1.77
-0.130
-6.84%
華盛通- 最 高1.86
- 今 開1.86
- 成交量 19.06万股
- 最 低 1.75
- 昨 收 1.90
- 總市值 5601.17万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.60%
- 52周最低 1.12
- 委 比 0.00%
- 總股本 3164.50万
- 歷史最高 7.00
- 量 比 0.61
- 振 幅 5.79%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OS Therapies Releases Investor Presentation for Stakeholders
OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On October...
10-18 05:28
OS Therapies Granted Second Type C Meeting From U.S. Food & Drug Administration For Biologics Licensing Application Of OST-HER2 To Treat Pulmonary Metastatic Osteosarcoma
Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma
10-17 21:20
OS Therapies Announces Positive Regulatory Update Following October 6 Meeting With EMA Rapporteur, Dutch Medicines Evaluation Board
Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma settings, supported
10-09 19:43
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
09-12 23:22
OS Therapies To Release Updated 2-Yr Survival Data For OST-HER2 In Phase 2b Osteosarcoma Trial On October 10, 2025
Concurrent with this announcement, the Company announced that updated 2-year overall survival data from all 40 patients in the Company's Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully
09-12 19:44
OS Therapies Raises $3.7M for OST-HER2 Launch
The latest announcement is out from OS Therapies Incorporated ( ($OSTX) ). On S...
09-03 04:50
OS Therapies To Provide FDA Meeting Update On OST-HER2 Regulatory Path For Osteosarcoma On September 2, 2025
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed
08-28 04:13
OS Therapies Reports Progress in Osteosarcoma Treatment
OS Therapies Incorporated ( ($OSTX) ) has released its Q2 earnings. Here is a b...
08-26 12:01
OS Therapies reports Q2 results
OS Therapies press release (NYSE:OSTX): Q2 Reported final EFS data (35% vs. 20%, p = 0.0197) showing a statistically significant benefit from the Company's 40 patient Phase 2b clinical trial for OST-...
08-20 03:21
